My guess is that the report will conclude there is still a market for an IIH treatment.
The GLP-1 drugs are useful tools in weight loss but they aren't immediate or universally effective. They are certainly less effective than weight loss surgery, a treatment that has been available for many years.
The report may conclude that the market size is no longer as large as first estimated. Even if it is half the original estimate though, it is still a compelling investment case.
Add to My Watchlist
What is My Watchlist?
